Full-Scale Advancement of Anticancer ADC Platform
Accelerating Next-Generation ADC Technology Development
Advancing the 'E-MASK TA-MUC1 ADC' Platform

On July 6, Hongcheon-gun, Gangwon Province (Governor Shin Youngjae), announced that Cyron Therapeutics (CEO Yoon Sangsoon), a resident company of the Hongcheon National Antibody Cluster, has been selected for the Opportunity Development Zone project under the "Regional Innovation Cluster Development (R&D)" program, which is promoted by the Ministry of Trade, Industry and Energy and supervised by the Korea Institute for Advancement of Technology (KIAT).

Hongcheon National Antibody Cluster. Provided by Hongcheon County

Hongcheon National Antibody Cluster. Provided by Hongcheon County

View original image

Cyron Therapeutics will begin full-scale advancement of its next-generation antibody-drug conjugate (ADC) platform, the 'E-MASK TA-MUC1 ADC.' This project will be carried out jointly with the Scripps Korea Antibody Institute.


This program is a key national R&D initiative that identifies promising, technologically advanced companies based on regionally specialized industries and supports their research and development.


With this selection, Cyron Therapeutics will focus on enhancing the anticancer efficacy of its TA-MUC1-targeted ADC platform and developing technology to reduce off-target absorption (Sink effect). The company plans to invest a total of KRW 2.7 billion in research and development by 2028.


The core technology, 'E-MASK TA-MUC1 ADC,' is a next-generation anticancer therapy that precisely targets specific antigens present in cancer cells to selectively activate therapeutic effects. It is characterized by improving tumor delivery efficiency by reducing the drug inefficiency caused by soluble MUC1—a problem identified in existing therapies—thereby minimizing the Sink effect.


Additionally, it is designed to minimize on-target off-tumor side effects that affect normal cells, thereby increasing its potential as a precision cancer therapy.


The scope of research and development includes antibody design, optimization of antibody-drug conjugation, non-clinical efficacy evaluation, in vivo distribution and pharmacokinetic analysis, and single-dose toxicity assessment in primates, covering the entire non-clinical development cycle.


Cyron Therapeutics plans to actively leverage the research infrastructure of the Hongcheon National Antibody Cluster in line with Gangwon Special Self-Governing Province's policy to nurture the bioindustry. By collaborating with the Scripps Korea Antibody Institute, the company aims to accelerate global technology transfer and commercialization outcomes.


CEO Yoon Sangsoon said, "This national R&D project will serve as an opportunity to further advance our E-MASK-based ADC platform technology," adding, "We will strengthen our non-clinical competitiveness through cooperation with research institutions and pursue global technology transfer."



An official from Hongcheon-gun stated, "The selection for this project is a remarkable achievement that proves the outstanding technological capabilities of the resident companies at the Hongcheon National Antibody Cluster," and added, "We will continue to expand research infrastructure and provide administrative support so that promising bio companies like Cyron Therapeutics can grow into internationally competitive enterprises."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing